The FNY UA1290 System brings together two coordinated products: the UA1290 Pomegranate Drink and the UA1290 Probiotic Solid Beverage. The concept combines pomegranate-derived ellagitannins with the named CCFM1290 probiotic in a convenient two-product nutritional system.
The biochemical pathway shown on the original poster is a product claim requiring supporting scientific and regulatory documentation. These products are not intended to diagnose, treat, cure or prevent disease.

The UA1290 concept is not presented as an ordinary single-ingredient supplement. It combines a pomegranate drink with a separate probiotic solid beverage. Each product has a distinct role within the proposed nutritional concept.

The pomegranate drink provides the fruit-based component of the system. The poster highlights naturally occurring pomegranate ellagitannins as the principal compounds behind the UA1290 concept.

The probiotic solid beverage is presented as the microbial component of the system. The poster specifically identifies CCFM1290 as the featured probiotic.
The FNY UA1290 System is a coordinated nutritional-product concept containing the UA1290 Pomegranate Drink and the UA1290 Probiotic Solid Beverage. The original poster states that pomegranate ellagitannins may be hydrolysed into ellagic acid and then interact with the CCFM1290 probiotic in a proposed pathway associated with the production of a compound described as “UA.”
The identity of UA, the conditions required for its production and the extent of this effect in humans must be confirmed from official scientific and regulatory documentation.
The poster identifies ellagitannins naturally present in pomegranate as the starting compounds.
The poster states that ellagitannins may be hydrolysed in the stomach and intestinal tract to form ellagic acid.
The UA1290 Probiotic Solid Beverage contains the named CCFM1290 probiotic, subject to confirmation from the approved product specification.
The poster proposes that the interaction may contribute to the body’s production of a compound described as UA.
This pathway must not be described as clinically proven until FNY supplies studies identifying the UA compound, study design, participants, dosage, endpoints and results.
Pomegranate is the botanical foundation of the UA1290 Pomegranate Drink. Its ellagitannins are central to the mechanism proposed in the product poster.
CCFM1290 is the specifically named probiotic featured in the UA1290 Probiotic Solid Beverage. Its full strain identity, viable count and storage requirements must be confirmed from the approved specification.
Separate drink and probiotic sachets allow the two products to retain their distinct formats within one coordinated nutritional system.
UA1290 combines a pomegranate product and a named probiotic product within one coordinated system.
The poster identifies CCFM1290 rather than referring only to generic probiotics.
The product concept brings together pomegranate-derived compounds and a probiotic solid beverage.
Customers can request the complete formulation, directions, strain information and supporting evidence before purchasing.
An advanced product concept should be supported by clear documentation. Before purchasing or distributing UA1290, customers and partners should be able to review the complete ingredients, strain identification, serving directions, safety information and evidence supporting the proposed biochemical pathway.
The supplied poster does not show sufficiently clear preparation, dosage or timing instructions for either product. Follow only the approved labels supplied for the country in which the products are sold.
Do not guess dosage or instruct customers to consume the products together until this is confirmed by the approved label.
Probiotic and botanical products may not be suitable for every individual. Product suitability depends on the complete formula, dose, health status and medicines being used.
The FNY UA1290 products are nutritional products and do not replace prescribed medication, medical diagnosis, a balanced diet or professional healthcare.
It is a two-product nutritional concept consisting of the UA1290 Pomegranate Drink and UA1290 Probiotic Solid Beverage.
No. One is a pomegranate drink and the other is a probiotic solid beverage featuring CCFM1290.
Ellagitannins are naturally occurring plant compounds found in pomegranate. The poster identifies them as the starting compounds in the proposed UA1290 pathway.
CCFM1290 is the probiotic name displayed on the UA1290 poster. Its complete strain identity, viable count and technical specification should be obtained from FNY’s official product documents.
The supplied poster uses the abbreviation UA but does not provide enough documentation to confirm its full identity. FNY should provide the official technical definition before the abbreviation is expanded on this page.
The poster proposes a pathway involving pomegranate compounds and CCFM1290. The extent and consistency of any such production in humans require supporting scientific evidence and cannot be guaranteed.
No. These products must not be presented as medical or anti-ageing treatments. They are nutritional products.
The supplied poster presents them as a coordinated system, but the exact consumption protocol must be confirmed from the approved product directions.
Follow the approved label for each product. The supplied poster does not provide sufficiently clear dosage and preparation instructions.
No. Do not stop or change prescribed medication without professional medical advice.
Follow the storage instructions on each approved label. Probiotic products may have specific heat and moisture requirements.

UA1290 combines a pomegranate-based drink with a separately formulated CCFM1290 probiotic solid beverage. Before ordering, request the complete formulation, approved directions, safety information and scientific documentation from an FNY product adviser.
Product formulations, availability and authorised claims may differ between countries. These products are not intended to diagnose, treat, cure or prevent disease.